These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30706396)

  • 21. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
    Fukuhara H; Takeshima Y; Todo T
    Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses.
    Xiao H; Hu H; Guo Y; Li J; Zeng WB; Luo MH; Wang M; Hu Z
    ACS Synth Biol; 2024 Oct; 13(10):3268-3280. PubMed ID: 39358309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. oHSV Genome Editing by Means of galK Recombineering.
    Menotti L; Leoni V; Gatta V; Petrovic B; Vannini A; Pepe S; Gianni T; Campadelli-Fiume G
    Methods Mol Biol; 2020; 2060():131-151. PubMed ID: 31617176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1.
    Kalke K; Orpana J; Lasanen T; Esparta O; Lund LM; Frejborg F; Vuorinen T; Paavilainen H; Hukkanen V
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.
    Hu Z; Li Y; Yang J; Liu J; Zhou H; Sun C; Tian C; Zhu C; Shao M; Wang S; Wei L; Liu M; Li S; Wang J; Xu H; Zhu W; Li X; Li J
    Sci Rep; 2024 Oct; 14(1):23671. PubMed ID: 39389985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic HSV-1 suppresses cell invasion through downregulating Sp1 in experimental glioblastoma.
    Zhang J; Wang J; Li M; Su X; Tian Y; Wang P; Zhou X; Jin G; Liu F
    Cell Signal; 2023 Mar; 103():110581. PubMed ID: 36572188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cloning of the herpes simplex virus type 1 genome as a novel luciferase-tagged infectious bacterial artificial chromosome.
    Li Y; Wang S; Zhu H; Zheng C
    Arch Virol; 2011 Dec; 156(12):2267-72. PubMed ID: 21894520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.
    Nguyen HM; Sah N; Humphrey MRM; Rabkin SD; Saha D
    J Vis Exp; 2021 May; (171):. PubMed ID: 34057449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.